BlueWhale Bio provides the Synecta™ platform, which uses cell‑derived nanoparticle reagents to mimic natural immune activation and accelerate the expansion of CAR‑engineered and other immune‑cell therapies. The technology streamlines manufacturing, delivering more potent cell products faster and at lower cost, and is recognized as an FDA Advanced Manufacturing Technology for biotech and pharma developers of autologous cell therapies.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DVFounders
Product
Problem
Manufacturers of cell-based therapies often face inconsistent cell activation, lengthy expansion processes, and high production costs, which limit the ability to treat larger patient populations and achieve consistent therapeutic potency.
Solution
BlueWhale Bio’s Synecta™ platform provides an activation and expansion solution that uses cell‑derived nanoparticles to mimic natural immune cell activation. This approach streamlines the manufacturing workflow, delivering more potent cell products in a shorter time frame while reducing operational expenses. The technology has been recognized as an FDA Advanced Manufacturing Technology, underscoring its regulatory relevance and potential to improve scalability for cell therapy programs.
Target Audience
Primary customers are biotech and pharmaceutical companies developing autologous cell therapies such as CAR‑T, CAR‑NK, and other immune‑cell–based products.
Features
- Cell‑derived nanoparticle reagents that reproduce physiological activation signals for immune cells
- Accelerated proliferation of CAR‑engineered cells, enabling faster attainment of target dose levels
- Simplified, robust workflow that reduces hands‑on time and minimizes process variability
- Demonstrated cost savings through reduced reagent usage and shorter culture durations
- FDA Advanced Manufacturing Technology (AMT) designation, supporting regulatory confidence